{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T05:06:52Z","timestamp":1781327212368,"version":"3.54.1"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T00:00:00Z","timestamp":1534377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The study was funded by the Hellenic Scientific Society for the Study of AIDS and Sexually Transmitted Diseases."}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0202109","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T17:36:32Z","timestamp":1534440992000},"page":"e0202109","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":29,"title":["HCV elimination among people who inject drugs. Modelling pre- and post\u2013WHO elimination era"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6584-0313","authenticated-orcid":true,"given":"Ilias","family":"Gountas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vana","family":"Sypsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9252-7576","authenticated-orcid":true,"given":"Sarah","family":"Blach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homie","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelos","family":"Hatzakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,8,16]]},"reference":[{"issue":"9791","key":"ref1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews","volume":"378","author":"PK Nelson","year":"2011","journal-title":"Lancet"},{"issue":"Suppl 2","key":"ref2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1478-3231.2011.02539.x","article-title":"A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel","volume":"31","author":"M Cornberg","year":"2011","journal-title":"Liver international: official journal of the International Association for the Study of the Liver"},{"issue":"17","key":"ref3","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"JJ Feld","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"MS Sulkowski","year":"2014","journal-title":"The New England journal of medicine"},{"key":"ref5","unstructured":"WHO. Global Health Sector Strategy on viral hepatitis, 2016\u20132021 2015 [cited 2015 28\/10]. Available from: http:\/\/www.who.int\/hiv\/draft-hep-strategy-2016-2021_en.pdf<\/ext-link>."},{"issue":"6","key":"ref6","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S1473-3099(14)70704-2","article-title":"Elimination on the agenda for hepatitis C","volume":"14","author":"T Burki","year":"2014","journal-title":"The Lancet Infectious diseases"},{"key":"ref7","article-title":"Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model","author":"N Scott","year":"2016","journal-title":"Gut"},{"key":"ref8","article-title":"Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?","author":"I Gountas","year":"2017","journal-title":"Addiction"},{"key":"ref9","article-title":"How to eliminate HCV infection by antiviral treatment","author":"NK Martin","year":"2017","journal-title":"J Hepatol"},{"key":"ref10","article-title":"Hepatitis c treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs","author":"A Cousien","year":"2015","journal-title":"Hepatology"},{"issue":"10","key":"ref11","doi-asserted-by":"crossref","first-page":"638","DOI":"10.5694\/mja11.10981","article-title":"Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia","volume":"196","author":"ME Hellard","year":"2012","journal-title":"The Medical journal of Australia"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.26431","article-title":"Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals","volume":"58","author":"NK Martin","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hep.24656","article-title":"Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations","volume":"55","author":"NK Martin","year":"2012","journal-title":"Hepatology"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.28227","article-title":"Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs","volume":"63","author":"A Cousien","year":"2016","journal-title":"Hepatology"},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1111\/add.12750","article-title":"Commentary on Nolan et al. (2014): Opiate substitution treatment and hepatitis C virus prevention: building an evidence base?","volume":"109","author":"P Vickerman","year":"2014","journal-title":"Addiction"},{"issue":"Suppl 2","key":"ref16","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1093\/cid\/cit296","article-title":"Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy","volume":"57","author":"NK Martin","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1365-2893.2008.01041.x","article-title":"A comparison between the force of infection estimates for blood-borne viruses in injecting drug user populations across the European Union: a modelling study","volume":"15","author":"AJ Sutton","year":"2008","journal-title":"Journal of viral hepatitis"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/aje\/kwp141","article-title":"Hepatitis C infection among injecting drug users in England and Wales (1992\u20132006): there and back again?","volume":"170","author":"MJ Sweeting","year":"2009","journal-title":"American journal of epidemiology"},{"key":"ref19","first-page":"CD012021","article-title":"Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs","volume":"9","author":"L Platt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1111\/j.1360-0443.2011.03515.x","article-title":"The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence","volume":"106","author":"KM Turner","year":"2011","journal-title":"Addiction"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies","volume":"13","author":"JM Micallef","year":"2006","journal-title":"J Viral Hepat"},{"issue":"2","key":"ref22","first-page":"227","article-title":"Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium","volume":"79","author":"C Mathei","year":"2016","journal-title":"Acta Gastroenterol Belg"},{"key":"ref23","first-page":"w14543","article-title":"Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030","volume":"147","author":"P Bruggmann","year":"2017","journal-title":"Swiss Med Wkly"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1186\/s12889-016-3545-4","article-title":"High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011\u201314)","volume":"16","author":"B Wenz","year":"2016","journal-title":"BMC Public Health"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jhep.2017.10.010","article-title":"Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe","volume":"68","author":"H Fraser","year":"2018","journal-title":"J Hepatol"},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/jmv.23370","article-title":"Hepatitis C virus infection among drug addicts in Italy","volume":"84","author":"T Stroffolini","year":"2012","journal-title":"J Med Virol"},{"key":"ref27","unstructured":"Razavi-Shearer D DO, Kielland KB, Razavi H, W\u00fcsthoff LE, Midgard H. Reinfection of Hepatitis C Among People Who Inject Drugs in Norway: Opportunity for Intervention\u2014A Modelling Study. 5th International Symposium on Hepatitis Care in Substance Users; Oslo, Norway2016."},{"key":"ref28","author":"FC Homie Razavi","year":"2015"},{"issue":"Suppl 6","key":"ref29","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1186\/1471-2334-14-S6-S12","article-title":"Hepatitis C virus seroprevalence among people who inject drugs and factors associated with infection in eight Russian cities","volume":"14","author":"R Heimer","year":"2014","journal-title":"BMC Infect Dis"},{"key":"ref30","unstructured":"EMCDDA. Statistical Bulletin 2017\u2014health and social responses European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2017. Available from: http:\/\/www.emcdda.europa.eu\/data\/stats2017\/hsr_en<\/ext-link>."},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/0962280208094704","article-title":"Estimating the prevalence of ex-injecting drug use in the population","volume":"18","author":"M Sweeting","year":"2009","journal-title":"Statistical methods in medical research"},{"issue":"26","key":"ref32","first-page":"603","article-title":"Recommendations for follow-up of health-care workers after occupational exposure to hepatitis C virus","volume":"46","year":"1997","journal-title":"MMWR Morbidity and mortality weekly report"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"c5475","DOI":"10.1136\/bmj.c5475","article-title":"Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database","volume":"341","author":"R Cornish","year":"2010","journal-title":"Bmj"},{"issue":"Issue 3","key":"ref34","first-page":"200","article-title":"Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study","volume":"2","author":"Nazrul Islam","year":"2017","journal-title":"The Lancet"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"EJ Gane","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","article-title":"Exploratory study of oral combination antiviral therapy for hepatitis C","volume":"368","author":"F Poordad","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"e78286","DOI":"10.1371\/journal.pone.0078286","article-title":"Hepatitis C transmission and treatment in contact networks of people who inject drugs","volume":"8","author":"DA Rolls","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"ref38","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/cid\/civ948","article-title":"Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis","volume":"62","author":"B Simmons","year":"2016","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"Suppl 2","key":"ref39","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1093\/cid\/cit301","article-title":"Hepatitis C virus reinfection following treatment among people who use drugs","volume":"57","author":"BP Grady","year":"2013","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jhep.2016.02.007","article-title":"Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation","volume":"65","author":"NK Martin","year":"2016","journal-title":"J Hepatol"},{"issue":"12","key":"ref41","doi-asserted-by":"crossref","first-page":"e0143836","DOI":"10.1371\/journal.pone.0143836","article-title":"Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?","volume":"10","author":"VD Lima","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"ref42","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/add.13948","article-title":"Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic","volume":"113","author":"H Fraser","year":"2018","journal-title":"Addiction"},{"issue":"7","key":"ref43","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/cid\/civ438","article-title":"HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials","volume":"61","author":"SD Shafran","year":"2015","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0202109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T08:40:38Z","timestamp":1720514438000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0202109"}},"subtitle":[],"editor":[{"given":"Yury E.","family":"Khudyakov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,8,16]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0202109","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,16]]}}}